Abstract
Arginine is added to commercially-available recombinant tissue plasminogen activator (rtPA) to promote its solubility. However, arginine is also known to inhibit certain proteases. To explore the possibility that arginine inhibits the highly concentrated rtPA in commercial formulations, we tested the amino acid in assays of rtPA function. Although arginine was found to inhibit rtPA cleavage of a chromogenic substrate, it did not interfere with rtPA-mediated fibrinolysis. However, whole-blood clotting time and thrombin clotting time of purified fibrinogen were prolonged by arginine. Therefore, the concentration of arginine in commercial preparations of rtPA appears to have an anticoagulant effect but does not retard fibrinolysis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
